Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy

Per Holmgren, Marianne Lindskog, Bo von Schoultz
In: Maturitas · 1989 · vol. 11(1) , pp. 55–63 · doi:10.1016/0378-5122(89)90120-5 · PMID:2498619 · W2018011684
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-28 ⓘ

This study evaluated silicone vaginal rings for continuous low-dose oestradiol release in postmenopausal women, finding that 7 micrograms per day effectively alleviated urogenital atrophy symptoms with minimal systemic metabolic response.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Silicone vaginal rings for the continuous release of 17 beta-oestradiol (E2) with 2 constant in vitro release rates were used for the treatment of symptoms of urogenital atrophy in 2 groups of postmenopausal women. The very low dose of 7 micrograms/24 h was found to alleviate atrophic symptoms effectively and to induce significant maturation of vaginal and urethral epithelium. After a brief initial peak, the serum levels of E2 over 3 mth of treatment remained close to the detection limit. The 'undetectable' E2 release pattern was reflected only in increased levels of oestrone sulphate. There was no evidence of a systemic metabolic response and patient acceptance of the method was excellent. Continuous low-dose release of E2 via vaginal rings consequently offers an alternative means of administering local oestrogen therapy which may be particularly suitable for geriatric patients.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

References (19)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-18T06:25:56.777850+00:00
License: CC0 · commercial use OK